KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Operating Leases (2021 - 2025)

Castle Biosciences' Operating Leases history spans 5 years, with the latest figure at $26.5 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 85.03% year-over-year to $26.5 million; the TTM value through Dec 2025 reached $26.5 million, up 85.03%, while the annual FY2025 figure was $26.5 million, 85.03% up from the prior year.
  • Operating Leases for Q4 2025 was $26.5 million at Castle Biosciences, up from $25.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $26.5 million in Q4 2025 and bottomed at $6.5 million in Q2 2022.
  • The 5-year median for Operating Leases is $13.6 million (2024), against an average of $14.3 million.
  • The largest annual shift saw Operating Leases surged 91.77% in 2023 before it grew 1.21% in 2024.
  • A 5-year view of Operating Leases shows it stood at $6.9 million in 2021, then skyrocketed by 67.14% to $11.5 million in 2022, then grew by 22.89% to $14.2 million in 2023, then increased by 1.21% to $14.3 million in 2024, then soared by 85.03% to $26.5 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Operating Leases are $26.5 million (Q4 2025), $25.3 million (Q3 2025), and $25.4 million (Q2 2025).